APP and Alzheimer disease: The future of γ-secretase inhibition as an AD treatment strategy may depend on two newer strategies: first, the successful development of APP selective ‘Notch-sparing’ γ-secretase inhibitor compounds, capable of lowering Aβ levels without inhibiting the processing of Notch [148]; second, the development of γ-secretase modulators, which aim to cause a shift from Aβ1–42 species toward the shorter and less pathogenic forms of Aβ, while also sparing Notch [149].